NCT01323933View on ClinicalTrials.gov

First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

32

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

March 31, 2012

Study Completion Date

March 31, 2012

Conditions

Neoplasms

Interventions

DRUG

AB0024

Comparison of different dosages of drug

Trial Locations (2)

48201

Karmanos Cancer Institute, Detroit

78229

South Texas Accelerated Research Therapeutics, San Antonio

Sponsors

Lead Sponsor

Gilead Sciences

All Listed Sponsors

lead

Gilead Sciences

INDUSTRY

NCT01323933 - First-in-human Study of AB0024 to Evaluate Safety and Tolerability in Adults With Advanced Solid Tumors | Biotech Hunter | Biotech Hunter